We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current FDMT market cap is 269.51M. The company's latest EPS is USD -2.1813 and P/E is -2.67.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.2M | -19k | 28k | 5k | 3k |
| Operating Income | -13.97M | -36.65M | -38.14M | -42.46M | -51.13M |
| Net Income | -10.26M | -32.28M | -32.4M | -34.95M | -43.84M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.99M | 13.61M | 18.04M | 3.13M | 20.72M |
| Operating Income | -50.76M | -56.66M | -71.33M | -110.03M | -112.87M |
| Net Income | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 361.61M | 339.89M | 629.88M | 620.12M | 604.03M |
| Total Liabilities | 31.68M | 32.06M | 29.32M | 31.78M | 51.08M |
| Total Equity | 329.93M | 307.83M | 600.56M | 588.34M | 552.95M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 58.23M | 288.33M | 353.49M | 261.85M | 339.89M |
| Total Liabilities | 131.2M | 31.94M | 34.38M | 30.51M | 32.06M |
| Total Equity | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -51.14M | -75.79M | -29.09M | -59.33M | -88.72M |
| Investing | 122.4M | 115.72M | -263.26M | -336.8M | -309.5M |
| Financing | 152.07M | 156.83M | 318.83M | 336.08M | 336.65M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -36.71M | -50.91M | -69.13M | -86.69M | -75.79M |
| Investing | -3.2M | -1M | -172.68M | -17.05M | 115.72M |
| Financing | -2.2M | 278.98M | 118.09M | 3.09M | 156.83M |
| Market Cap | 269.51M |
| Price to Earnings Ratio | -2.67 |
| Price to Sales Ratio | 12.98 |
| Price to Cash Ratio | 1.08 |
| Price to Book Ratio | 0.87 |
| Dividend Yield | - |
| Shares Outstanding | 46.23M |
| Average Volume (1 week) | 1.02M |
| Average Volume (1 Month) | 1.09M |
| 52 Week Change | -72.95% |
| 52 Week High | 36.25 |
| 52 Week Low | 5.22 |
| Spread (Intraday) | 0.73 (11.59%) |
| Company Name | 4D Molecular Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.4dmoleculartherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
